ClinicalTrials.gg
CompletedNCT01960842Updated May 30, 2018Results posted

A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications

A Phase 3 interventional study of Levodopa-carbidopa intestinal gel and CADD-Legacy® 1400 ambulatory infusion pump in Advanced Parkinson's Disease, sponsored by AbbVie. Completed. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2018-05-30.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing levodopa in Parkinson Disease — 3 open to participants now, 3 under way, none of them phase 3. Levodopa · Parkinson Disease.

Enrollment
36th of 50
31 · median 56
Started
2013
with 2 others
Phase 3
12 of 51
none open now
Registered
33rd of 51
by date
Lead sponsor
3 of 51
AbbVie

Among the 51 studies testing levodopa in Parkinson Disease, this one is the 36th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2013, is one of 12 in phase 3, and was the 33rd registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 51 studies testing levodopa in Parkinson Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About levodopa

Levodopa: first FDA approval 1970 (LARODOPA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing levodopa in Parkinson Disease, or all of them as a file.
02

Study summary

The primary objective of this study is to measure the efficacy of ABT-SLV187 in subjects with advanced Parkinson's disease.

Read the detailed description

The study was composed of a screening period followed by 2 sequential on-treatment periods, as follows:

  • Screening Period (up to 28 days): determination of eligibility and discontinuation of antiparkinsonian disease medications other than levodopa-carbidopa immediate release (LC-oral) prior to nasojejunal (N-J) tube placement.
  • N-J Test Period (2 to 14 days): first hospitalization period, Baseline assessments, placement of N-J tube, and optimization of levodopa-carbidopa intestinal gel (LCIG) treatment via N-J tube and infusion pump (participant was hospitalized for N-J tube placement but hospitalization was not required for entire duration of LCIG treatment optimization).
  • PEG-J Period (12 weeks): second hospitalization period; placement of PEG-J tube; further optimization of LCIG treatment.
03

Conditions studied

  • Advanced Parkinson's Disease

Browse trials for

Keywords

  • levodopa
  • Advanced Parkinson's Disease
  • carbidopa
  • levodopa-carbidopa intestinal gel
  • Safety and Efficacy
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of idiopathic Parkinson's disease according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria.
  2. Subjects have 4 or 5 in modified Hohn and Yahr (H \& Y) classification of disease severity at "Off" state determined by the UPDRS Part V at Screening Visit 1.
  3. The subject's advanced Parkinson's disease must be levodopa-responsive as judged by the Investigator.
  4. Subjects have had optimal treatment with available Parkinson's disease medication as defined by local standards of care and, based upon the judgment of the Investigator, and their symptoms are judged inadequately controlled on this optimized treatment. Optimized treatment is defined as the maximum therapeutic effect obtained with available anti-parkinsonian pharmacological therapy when no further improvement is expected regardless of any additional manipulations of levodopa and/or other anti parkinsonian medication; this will be based on the Investigator's best clinical judgment.
  5. Presence of a recognizable "Off" and "On" state (motor fluctuations) as confirmed by UPDRS Part III (in both "On" and "Off" states), and by the Parkinson's Disease Diary© which must be observed and confirmed at Screening Visit 1.
  6. Subjects must be experiencing a minimum of 3 hours per day of "Off" time, as estimated by the Investigator and supported by the UPDRS at Screening Visit 1 and the Parkinson's Disease Diaries at baseline. The "Off" time must occur during a continuous 16-hour interval, including the portion of the day during which the subject is awake the majority of the time (e.g., 5 AM to 9 PM, 7 AM to 11 PM).

Exclusion criteria

Exclusion Criteria:

  1. Parkinson's disease diagnosis is unclear or a suspicion of other parkinsonian syndromes exists, such as secondary Parkinsonism (caused by drugs, toxins, infectious agents, vascular disease, trauma, brain neoplasm), Parkinson's-plus syndromes (e.g., multiple system atrophy, progressive supranuclear palsy) or the other neurodegenerative diseases that might mimic the symptoms of Parkinson's disease .
  2. Subjects who have undergone neurosurgery for the treatment of Parkinson's disease .
  3. Current primary psychiatric diagnosis of acute psychotic disorder or other uncontrolled primary psychiatric diagnoses, (e.g., bipolar disorder or major depressive disorder per 4th edition, Text Revision (DSM-IV-TR) criteria.
  4. Alzheimer's disease; or other significant cognitive impairment or dementia (defined as (MMSE) total score \< 24).
  5. Subject has significant current suicidal ideation within the previous year as evidenced by answering "yes" to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) completed at Screening or any history of suicide attempts.
  6. A low B12 level or low-normal B12 level (less than 300 pg/mL) with elevated methylmalonic acid (MMA). Note: Abnormal Vitamin B12 of questionable clinical significance (i.e., indeterminate or low normal results) prior to or at Screening Visit 2 require appropriate interpretation in conjunction with MMA and homocysteine laboratory values prior to proceeding further into the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Levodopa-Carbidopa Intestinal Gel (LCIG)

    All participants received LCIG via the N-J tube during the nasojejunal (N-J) Test Period and delivered to the proximal small intestine via percutaneous endoscopic gastrostomy - with jejunal extension tube (PEG-J) during the Post-PEG-J Long-Term Treatment Period. The starting dose was individually determined based on the daily dose of oral levodopa prior to study enrollment. The infusion dose was individually optimized for each participant on the basis of response and potential adverse events. During the PEG-J Period, LCIG was expected to be infused continuously over approximately 16 hours daily with a rate of infusion ranging from 1 to 10 mL/hour (20 to 200 mg of levodopa/hour).

    Drug: Levodopa-carbidopa intestinal gel · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: PEG tube · Device: J-tube

Interventions

  • DrugLevodopa-carbidopa intestinal gel

    Drug pages: Levodopa · Carbidopa

    Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)

    Also known as: ABT-SLV187, LCIG

  • DeviceCADD-Legacy® 1400 ambulatory infusion pump
  • DevicePEG tube

    percutaneous endoscopic gastrostomy tube

  • DeviceJ-tube

    jejunal tube

06

What researchers measure

Primary outcomes

  1. Average Daily Normalized "Off" Time: Change From Baseline To The Final PEG-J Visit

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.

    Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)

Secondary outcomes

  1. Average Daily Normalized "On" Time Without Troublesome Dyskinesia: Change From Baseline To The Final PEG-J Visit

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from baseline for "on" time indicates improvement.

    Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)

  2. Parkinson's Disease Questionnaire (PDQ-39) Summary Index: Change From Baseline To The Final PEG-J Visit

    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.

    Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)

  3. Clinical Global Impression - Change (CGI-I) Score at the Final PEG-J Visit

    The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.

    Time frame: Final PEG-J Visit (up to week 12)

  4. Patient Global Impression of Change (PGI-C) Score at the Final PEG-J Visit

    The PGI-C is a 7-point response scale. The subjects were to rate their change in status from Screening Visit 1 using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The responses of "Minimally improved," "Much improved," and "Very much improved" on the PGI-C were used to define responders.

    Time frame: Final PEG-J Visit (up to week 12)

  5. Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score: Change From Baseline To The Final PEG-J Visit

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.

    Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)

  6. Unified Parkinson's Disease Rating Scale (UPDRS) Part IIl Score: Change From Baseline To The Final PEG-J Visit

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.

    Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)

  7. Average Daily Normalized "On" Time With Troublesome Dyskinesia: Change From Baseline To The Final PEG-J Visit

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from baseline for "on" time indicates improvement.

    Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)

  8. Parkinson's Disease Questionnaire (PDQ-39) Mobility, Emotional Well-Being, Stigma, Social Support, Cognition, Communication, and Bodily Discomfort Domain Scores: Change From Baseline To The Final PEG-J Visit

    The PDQ-39 is a self-administered questionnaire which comprises 39 items (each question answered on a 5-point scale) addressing 8 domains of health in Parkinson's disease patients: Mobility (e.g., fear of falling when walking) includes 10 questions; Emotional Well-being (e.g., feelings of isolation) includes 6 questions; Stigma (e.g., social embarrassment) includes 4 questions; Social Support includes 3 questions; Cognition includes 4 questions; Communication includes 3 questions; and Bodily Discomfort includes 3 questions. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)

  9. Unified Parkinson's Disease Rating Scale (UPDRS) Total Score: Change From Baseline To The Final PEG-J Visit

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0 to176, with 176 representing the worst (total) disability, and 0 representing no disability.

    Time frame: Baseline and Final PEG-J Visit (up to Week 12)

  10. Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score: Change From Baseline To The Final PEG-J Visit

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0 to 16 and higher scores are associated with more disability.

    Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)

  11. Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score: Change From Baseline To The Final PEG-J Visit

    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0 to 23 and higher scores are associated with more disability.

    Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)

  12. Average Daily Normalized "Off" Time Excluding Subjects Who Did Not Receive LCIG During the Entire PEG-J Period: Change From Baseline To The Final PEG-J Visit

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.

    Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)

  13. Average Daily Normalized "Off" Time Including All PD Diaries Regardless if They Were Completed After the Subject Had Used a Concomitant Anti-Parkinsonian Medication: Change From Baseline To The Final PEG-J Visit

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.

    Time frame: Baseline (end of screening period) and Final PEG-J Visit (up to week 12)

  14. Average Daily Normalized "Off" Time at Baseline and Each Visit: Change From Baseline To The Final PEG-J Visit

    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. n= the number of participants with available data at each time point.

    Time frame: Baseline (end of screening period) and Weeks 2, 4, 6, 8, 10, and 12

  15. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent AEs (TEAEs) are defined as any event that began or worsened in severity after N-J placement. The investigator assessed the relationship of each event to the use of study drug as Reasonable Possibility or No Reasonable Possibility. For more details on adverse events please see the AE section below.

    Time frame: From N-J placement to the end of study or early termination of treatment, including the removal of PEG-J (up to 17 weeks), plus 30 days.

  16. Number of Participants With Potentially Clinically Significant Vital Sign Parameters

    Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), body temperature (Temp), and baseline (BL). Increase and decrease are signified by ↑ and ↓, respectively.

    Time frame: From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)

  17. Number of Participants With Potentially Clinically Significant Values for Hematology Parameters

    Terms abbreviated in the table include females (f), males (m), and femtoliters (fL).

    Time frame: From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)

  18. Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters

    Terms abbreviated in the table include upper limit of normal (ULN), male (m), and female (f).

    Time frame: From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)

  19. Number of Participants With Potentially Clinically Significant Values for 12-lead Electrocardiogram (ECG)

    Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), QT interval corrected for heart rate using Fridericia's formula (QTcF), and baseline (BL). Increase and decrease are signified by ↑ and ↓, respectively. n = the number of participants with available data at each time point.

    Time frame: From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)

Other outcomes

  1. Neurological Examination

    Any abnormal findings are recorded as an adverse event after the first study drug administration; please see the AE section below. Further analysis for neurological examination findings was not performed per protocol.

    Time frame: From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)

  2. Physical Examination

    Any abnormal findings are recorded as an adverse event after the first study drug administration; please see the AE section below. Further analysis for physical examination findings was not performed per protocol.

    Time frame: From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)

07

Results

Posted Apr 20, 2016

Participant flow

Participant flow — Overall Study
MilestoneLevodopa-Carbidopa Intestinal Gel (LCIG)
Started31
Completed28
Not completed3
Withdrew: Adverse event1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryAverage Daily Normalized "Off" Time: Change From Baseline To The Final PEG-J Visit

Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.

Time frame:
Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Reported as:
Mean · hours
Average Daily Normalized "Off" Time: Change From Baseline To The Final PEG-J Visit
hoursLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline7.37 ± 2.263
Last PEG-J visit2.72 ± 2.320
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = <0.001 · Mean difference (net): -4.64 · 95% CI -5.78 to -3.50
SecondaryAverage Daily Normalized "On" Time Without Troublesome Dyskinesia: Change From Baseline To The Final PEG-J Visit

Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from baseline for "on" time indicates improvement.

Time frame:
Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Reported as:
Mean · hours
Average Daily Normalized "On" Time Without Troublesome Dyskinesia: Change From Baseline To The Final PEG-J Visit
hoursLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline7.52 ± 2.505
Last PEG-J visit13.10 ± 2.453
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = <0.001 · Mean difference (net): 5.58 · 95% CI 4.21 to 6.95
SecondaryParkinson's Disease Questionnaire (PDQ-39) Summary Index: Change From Baseline To The Final PEG-J Visit

The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.

Time frame:
Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Reported as:
Mean · units on a scale
Parkinson's Disease Questionnaire (PDQ-39) Summary Index: Change From Baseline To The Final PEG-J Visit
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline35.5 ± 13.75
Last PEG-J visit23.5 ± 13.59
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = <0.001 · Mean difference (net): -12.0 · 95% CI -16.3 to -7.7
SecondaryClinical Global Impression - Change (CGI-I) Score at the Final PEG-J Visit

The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.

Time frame:
Final PEG-J Visit (up to week 12)
Reported as:
Mean · units on a scale
Clinical Global Impression - Change (CGI-I) Score at the Final PEG-J Visit
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Clinical Global Impression - Change (CGI-I) Score at the Final PEG-J Visit1.9 ± 0.77
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · Wilcoxon signed-rank test · p = <0.001 · Mean change from score = 4: -2.1
SecondaryPatient Global Impression of Change (PGI-C) Score at the Final PEG-J Visit

The PGI-C is a 7-point response scale. The subjects were to rate their change in status from Screening Visit 1 using the following 7-point scale: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, 7 = Very much worse. The responses of "Minimally improved," "Much improved," and "Very much improved" on the PGI-C were used to define responders.

Time frame:
Final PEG-J Visit (up to week 12)
Reported as:
Mean · units on a scale
Patient Global Impression of Change (PGI-C) Score at the Final PEG-J Visit
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Patient Global Impression of Change (PGI-C) Score at the Final PEG-J Visit2.0 ± 0.94
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · Wilcoxon signed-rank test · p = <0.001 · Mean change from score = 4: -2.0
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS) Part II Score: Change From Baseline To The Final PEG-J Visit

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.

Time frame:
Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Reported as:
Mean · units on a scale
Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score: Change From Baseline To The Final PEG-J Visit
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline9.4 ± 6.63
Last PEG-J visit7.6 ± 6.93
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = =0.101 · Mean difference (net): -1.8 · 95% CI -4.0 to 0.4
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS) Part IIl Score: Change From Baseline To The Final PEG-J Visit

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.

Time frame:
Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Reported as:
Mean · units on a scale
Unified Parkinson's Disease Rating Scale (UPDRS) Part IIl Score: Change From Baseline To The Final PEG-J Visit
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline16.5 ± 9.70
Final PEG-J visit14.3 ± 11.30
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = =0.182 · Mean difference (net): -2.1 · 95% CI -5.3 to 1.1
SecondaryAverage Daily Normalized "On" Time With Troublesome Dyskinesia: Change From Baseline To The Final PEG-J Visit

Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from baseline for "on" time indicates improvement.

Time frame:
Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Reported as:
Mean · hours
Average Daily Normalized "On" Time With Troublesome Dyskinesia: Change From Baseline To The Final PEG-J Visit
hoursLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline1.12 ± 2.311
Last PEG-J visit0.12 ± 0.394
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = =0.032 · Mean difference (net): -1.00 · 95% CI -1.90 to -0.09
SecondaryParkinson's Disease Questionnaire (PDQ-39) Mobility, Emotional Well-Being, Stigma, Social Support, Cognition, Communication, and Bodily Discomfort Domain Scores: Change From Baseline To The Final PEG-J Visit

The PDQ-39 is a self-administered questionnaire which comprises 39 items (each question answered on a 5-point scale) addressing 8 domains of health in Parkinson's disease patients: Mobility (e.g., fear of falling when walking) includes 10 questions; Emotional Well-being (e.g., feelings of isolation) includes 6 questions; Stigma (e.g., social embarrassment) includes 4 questions; Social Support includes 3 questions; Cognition includes 4 questions; Communication includes 3 questions; and Bodily Discomfort includes 3 questions. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Reported as:
Mean · units on a scale
Parkinson's Disease Questionnaire (PDQ-39) Mobility, Emotional Well-Being, Stigma, Social Support, Cognition, Communication, and Bodily Discomfort Domain Scores: Change From Baseline To The Final PEG-J Visit
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Mobility Domain-Baseline55.7 ± 19.46
Mobility Domain-Last PEG-J visit36.5 ± 22.49
Emotional Well-Being Domain-Baseline30.8 ± 19.13
Emotional Well-Being Domain-Last PEG-J visit24.3 ± 18.02
Stigma Domain-Baseline20.6 ± 22.21
Stigma Domain-Last PEG-J visit13.1 ± 20.78
Social Support Domain-Baseline16.1 ± 18.69
Social Support Domain-Last PEG-J visit14.6 ± 21.35
Cognition Domain-Baseline28.5 ± 19.26
Cognition Domain-Last PEG-J visit14.6 ± 13.16
Communication Domain-Baseline13.3 ± 14.62
Communication Domain-Last PEG-J visit14.4 ± 16.94
Bodily Discomfort Domain-Baseline35.0 ± 21.60
Bodily Discomfort Domain-Last PEG-J visit17.2 ± 14.83
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = <0.001 · Mean difference (net): -19.2 · 95% CI -27.8 to -10.6
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = =0.059 · Mean difference (net): -6.5 · 95% CI -13.3 to 0.3
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = =0.070 · Mean difference (net): -7.5 · 95% CI -15.6 to 0.6
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = =0.591 · Mean difference (net): -1.5 · 95% CI -7.3 to 4.2
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = <0.001 · Mean difference (net): -14.0 · 95% CI -20.7 to -7.3
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = =0.670 · Mean difference (net): 1.1 · 95% CI -4.2 to 6.4
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = <0.001 · Mean difference (net): -17.8 · 95% CI -25.2 to -10.3
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS) Total Score: Change From Baseline To The Final PEG-J Visit

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0 to176, with 176 representing the worst (total) disability, and 0 representing no disability.

Time frame:
Baseline and Final PEG-J Visit (up to Week 12)
Reported as:
Mean · units on a scale
Unified Parkinson's Disease Rating Scale (UPDRS) Total Score: Change From Baseline To The Final PEG-J Visit
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline27.7 ± 15.53
Last PEG-J visit22.9 ± 17.53
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = =0.056 · Mean difference (net): -4.8 · 95% CI -9.8 to 0.1
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS) Part I Score: Change From Baseline To The Final PEG-J Visit

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0 to 16 and higher scores are associated with more disability.

Time frame:
Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Reported as:
Mean · units on a scale
Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score: Change From Baseline To The Final PEG-J Visit
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline1.8 ± 2.02
Last PEG-J visit0.9 ± 0.91
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = =0.011 · Mean difference (net): -0.9 · 95% CI -1.6 to -0.2
SecondaryUnified Parkinson's Disease Rating Scale (UPDRS) Part IV Score: Change From Baseline To The Final PEG-J Visit

The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0 to 23 and higher scores are associated with more disability.

Time frame:
Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Reported as:
Mean · units on a scale
Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score: Change From Baseline To The Final PEG-J Visit
units on a scaleLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline8.7 ± 3.15
Last PEG-J visit5.5 ± 3.08
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = <0.001 · Mean difference (net): -3.2 · 95% CI -4.4 to -1.9
SecondaryAverage Daily Normalized "Off" Time Excluding Subjects Who Did Not Receive LCIG During the Entire PEG-J Period: Change From Baseline To The Final PEG-J Visit

Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.

Time frame:
Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Reported as:
Mean · hours
Average Daily Normalized "Off" Time Excluding Subjects Who Did Not Receive LCIG During the Entire PEG-J Period: Change From Baseline To The Final PEG-J Visit
hoursLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline7.32 ± 2.290
Last PEG-J visit2.67 ± 2.341
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = <0.001 · Mean difference (net): -4.65 · 95% CI -5.83 to -3.47
SecondaryAverage Daily Normalized "Off" Time Including All PD Diaries Regardless if They Were Completed After the Subject Had Used a Concomitant Anti-Parkinsonian Medication: Change From Baseline To The Final PEG-J Visit

Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.

Time frame:
Baseline (end of screening period) and Final PEG-J Visit (up to week 12)
Reported as:
Mean · hours
Average Daily Normalized "Off" Time Including All PD Diaries Regardless if They Were Completed After the Subject Had Used a Concomitant Anti-Parkinsonian Medication: Change From Baseline To The Final PEG-J Visit
hoursLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline7.37 ± 2.263
Last PEG-J visit2.78 ± 2.382
Statistical analysis
  • Levodopa-Carbidopa Intestinal Gel (LCIG) · One-sample t-test, 2-sided · p = <0.001 · Mean difference (net): -4.58 · 95% CI -5.73 to -3.44
SecondaryAverage Daily Normalized "Off" Time at Baseline and Each Visit: Change From Baseline To The Final PEG-J Visit

Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. n= the number of participants with available data at each time point.

Time frame:
Baseline (end of screening period) and Weeks 2, 4, 6, 8, 10, and 12
Reported as:
Mean · hours
Average Daily Normalized "Off" Time at Baseline and Each Visit: Change From Baseline To The Final PEG-J Visit
hoursLevodopa-Carbidopa Intestinal Gel (LCIG)
Baseline (n=29)7.37 ± 2.263
Week 2 (n=29)3.17 ± 2.365
Week 4 (n=29)3.68 ± 3.077
Week 6 (n=29)2.61 ± 2.318
Week 8 (n=27)2.77 ± 2.324
Week 10 (n=27)2.47 ± 2.210
Week 12 (n=27)2.45 ± 2.094
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a participant which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent AEs (TEAEs) are defined as any event that began or worsened in severity after N-J placement. The investigator assessed the relationship of each event to the use of study drug as Reasonable Possibility or No Reasonable Possibility. For more details on adverse events please see the AE section below.

Time frame:
From N-J placement to the end of study or early termination of treatment, including the removal of PEG-J (up to 17 weeks), plus 30 days.
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
Any TEAE31
Any TEAE at least possibly related to LCIG0
Any TEAE at least possibly related to LCIG System30
Any severe TEAE2
Any SAE4
Any TEAE Leading to Discontinuation of Study1
Death1
Death related to AE1
SecondaryNumber of Participants With Potentially Clinically Significant Vital Sign Parameters

Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), body temperature (Temp), and baseline (BL). Increase and decrease are signified by ↑ and ↓, respectively.

Time frame:
From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Vital Sign Parameters
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
SuSBP <=90 and >30 mm Hg ↓ from BL3
SuSBP >=180 and >40 mm Hg ↑ from BL1
StSBP <=90 and >30 mm Hg ↓ from BL3
StSBP >=180 and >40 mm Hg ↑ from BL1
OSBP: ↓ >=30 mm Hg Supine to Standing8
SuDBP <=50 and >30 mm Hg ↓ from BL1
SuDBP >=105 and >30 mm Hg ↑ from BL1
StDBP <=50 and >30 mm Hg ↓ from BL3
StDBP >=105 and >30 mm Hg ↑ from BL3
ODBP: ↓ >=20 mm Hg Supine to Standing11
SuP <=50 and >30 bpm ↓ from BL0
SuP >=120 and >30 bpm ↑ from BL0
StP <=50 and >30 bpm ↓ from BL0
StP >=120 and >30 bpm ↑ from BL0
Weight <=7% ↓ from BL8
Weight >=7% ↑ from BL2
SecondaryNumber of Participants With Potentially Clinically Significant Values for Hematology Parameters

Terms abbreviated in the table include females (f), males (m), and femtoliters (fL).

Time frame:
From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Values for Hematology Parameters
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
Haemoglobin <90 g/L (f); <100 g/L (m)1
Haematocrit <30% (f); <34% (m)2
Red Blood Cells <2.0 10^12/L (f); <2.5 10^12/L (m)0
Platelet Count <95 10^9/L1
Platelet Count >700 10^9/L0
White Blood Cells <2.8 10^9/L0
White Blood Cells >16.0 10^9/L1
Lymphocytes >80%0
Monocytes >30%0
Eosinophils >10%1
Mean Corpuscular Volume <60 fL0
Mean Corpuscular Volume >120 fL0
SecondaryNumber of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters

Terms abbreviated in the table include upper limit of normal (ULN), male (m), and female (f).

Time frame:
From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
Alanine Aminotransferase >3xULN1
Aspartate Aminotransferase >3xULN1
Gamma-glutamyl Transferase >3x ULN0
Alkaline Phosphatase >400 U/L0
Total Bilirubin >2xULN0
Creatine Phosphokinase >3x ULN0
Creatinine >177 µmol/L0
Blood Urea Nitrogen >10.8 mmol/L2
Uric Acid>500µmol/L(f);>590µmol/L(m)0
Calcium <1.75 mmol/L0
Calcium >3.0 mmol/L0
Sodium <126 mmol/L0
Sodium >156 mmol/L0
Potassium <3.0 mmol/L1
Potassium >6.0 mmol/L0
Non-fasting Glucose <2.78 mmol/L1
Non-fasting Glucose >16.0 mmol/L1
Albumin <25 g/L1
Albumin >70 g/L0
Total Protein <45 g/L0
Cholesterol >12.9 mmol/L0
Triglycerides >5.6 mmol/L0
Lactate dehydrogenase >3x ULN0
SecondaryNumber of Participants With Potentially Clinically Significant Values for 12-lead Electrocardiogram (ECG)

Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), QT interval corrected for heart rate using Fridericia's formula (QTcF), and baseline (BL). Increase and decrease are signified by ↑ and ↓, respectively. n = the number of participants with available data at each time point.

Time frame:
From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Values for 12-lead Electrocardiogram (ECG)
participantsLevodopa-Carbidopa Intestinal Gel (LCIG)
HR <=50 and >30 bpm ↓ from BL (n=31)0
HR >=120 and >30 bpm ↑ from BL (n=31)0
PR Interval <120 msec (n=30)0
PR Interval >220 msec (n=30)1
QTcB Interval >480 msec (n=31)1
QTcB Interval >60 msec ↑ from BL (n=31)1
QTcF Interval >480 msec (n=31)0
QTcF Interval >60 msec ↑ from BL (n=31)1
Other pre-specifiedNeurological Examination

Any abnormal findings are recorded as an adverse event after the first study drug administration; please see the AE section below. Further analysis for neurological examination findings was not performed per protocol.

Time frame:
From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)

Results for this outcome have not been posted.

Other pre-specifiedPhysical Examination

Any abnormal findings are recorded as an adverse event after the first study drug administration; please see the AE section below. Further analysis for physical examination findings was not performed per protocol.

Time frame:
From Baseline (end of screening period) to Final PEG-J Visit (up to week 12)

Results for this outcome have not been posted.

Adverse events

Collected over From study enrollment to the end of study or early termination of treatment, including the removal of PEG-J (up to 17 weeks), plus 30 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levodopa-Carbidopa Intestinal Gel (LCIG)—4/31 (12.9%)31/31 (100%)
Most frequent serious events
Most frequent serious events
EventLevodopa-Carbidopa Intestinal Gel (LCIG)
PNEUMONIA ASPIRATIONRespiratory, thoracic and mediastinal disorders2/31
DISSEMINATED INTRAVASCULAR COAGULATIONBlood and lymphatic system disorders1/31
ABDOMINAL PAINGastrointestinal disorders1/31
CONSTIPATIONGastrointestinal disorders1/31
GASTROINTESTINAL PERFORATIONGastrointestinal disorders1/31
MELAENAGastrointestinal disorders1/31
DEVICE DISLOCATIONGeneral disorders1/31
DEVICE KINKGeneral disorders1/31
SEPSISInfections and infestations1/31
FEMUR FRACTUREInjury, poisoning and procedural complications1/31
Most frequent other events
Showing 10 of 102
Most frequent other events
EventLevodopa-Carbidopa Intestinal Gel (LCIG)
INCISION SITE PAINInjury, poisoning and procedural complications13/31
EXCESSIVE GRANULATION TISSUESkin and subcutaneous tissue disorders10/31
CONSTIPATIONGastrointestinal disorders6/31
DIARRHOEAGastrointestinal disorders6/31
NASOPHARYNGITISInfections and infestations6/31
FALLInjury, poisoning and procedural complications6/31
PROCEDURAL PAINInjury, poisoning and procedural complications5/31
BLOOD HOMOCYSTEINE INCREASEDInvestigations5/31
DYSKINESIANervous system disorders5/31
INCISION SITE ERYTHEMAInjury, poisoning and procedural complications4/31

Baseline characteristics

Safety Analysis Set: All subjects who had undergone the N-J placement procedure.

Age, Continuous
Age, Continuous(years)Levodopa-Carbidopa Intestinal Gel (LCIG)
Mean61.6 ± 10.50
Sex: Female, Male
Sex: Female, Male(Participants)Levodopa-Carbidopa Intestinal Gel (LCIG)
Female19
Male12
Duration of Parkinson's Disease Since Initial Diagnosis
Duration of Parkinson's Disease Since Initial Diagnosis(years)Levodopa-Carbidopa Intestinal Gel (LCIG)
Mean12.4 ± 5.08
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Murata M, Mihara M, Hasegawa K, Jeon B, Tsai CH, Nishikawa N, Oeda T, Yokoyama M, Robieson WZ, Ryman D, Eaton S, Chatamra K, Benesh J. Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson's disease patients. NPJ Parkinsons Dis. 2016 Nov 3;2:16020. doi: 10.1038/npjparkd.2016.20. eCollection 2016. PubMed 28725701 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2013
First posted
Oct 11, 2013
Start
Oct 2013
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Apr 20, 2016
Last update
May 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01960842
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 11, 2013
Start date
Oct 2013
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Apr 20, 2016
Last update
May 30, 2018

Study contacts

Masayoshi Yanagawa, PhD
study director · AbbVie Japan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levodopa · Carbidopa

Start the discussion